| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) |
| Formulation | 10 mg/ml concentrate for solution for infusion |
| Reference number | 4178 |
| Indication | In combination with cabozantinib for the first-line treatment of adult patients with advanced renal cell carcinoma |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/03/2021 |
| NICE guidance | TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma |